Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats

Food and Chemical Toxicology

Volumn 52, Issue , 2013, Pages 12-18

  Xin, Peng ^a   Han, Hao ^a   Gao, Danhong ^a   Cui, Wei ^a   Yang, Xuefeng ^a   Ying, Chenjiang ^a   Sun, Xiufa ^a   Hao, Liping ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Fatty acid synthase; Low density lipoprotein receptor; Nonalcoholic fatty liver disease; Resveratrol; Scavenger receptor class B type I; Thyroid hormone receptor 1

Indexed keywords

CHOLESTEROL; FATTY ACID SYNTHASE; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; RESVERATROL; SCAVENGER RECEPTOR BI; THYROID HORMONE RECEPTOR BETA; THYROID HORMONE RECEPTOR BETA1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENE EXPRESSION; GLUCOSE INTAKE; LIPID DIET; LIPID LIVER LEVEL; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION;

ANIMALS; ANTIGENS, CD95; ENERGY METABOLISM; FATTY LIVER; GENE EXPRESSION; LIPID METABOLISM; MALE; RATS; RATS, WISTAR; RECEPTORS, LDL; SCAVENGER RECEPTORS, CLASS B; STILBENES; THYROID HORMONE RECEPTORS BETA; WEIGHT GAIN;

RATTUS; RATTUS NORVEGICUS;

EID: 84869238321     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.10.026     Document Type: Article

References (40)

1. Ahn J., Cho I., Kim S., Kwon D., Ha T. Dietary resveratrol alters lipid metabolism-related gene expression of mice on an atherogenic diet. J. Hepatol. 2008, 49:1019-1028.
2. Bujanda L., Hijona E., Larzabal M., Beraza M., Aldazabal P., García-Urkia N., Sarasqueta C., Cosme A., Irastorza B., González A., Arenas J.I. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol. 2008, 8:40.
3. Brunet, R., How, M., Trigatti, B.L., 2011. Modulators of protein kinase C affect SR-BI-dependent HDL lipid uptake in transfected HepG2 cells. Cholesterol 687939.
4. Cao R., Ji A.L., Zhang W.B., Cao Z.P., Xiang X.S., Gao S.B., Wang F. Effect of conjugated linoleic acid on gene expression of lipidmetabolism enzymes and PPARC in liver of obese rats. Bull. Acad. Mil. Med. Sci. 2007, 31:42-49. (In Chinese).
5. Cano P., Jiménez-Ortega V., Larrad A., Reyes Toso C.F., Cardinali D.P. Effect of a high-fat diet on 24-h pattern of circulating levels of prolactin, luteinizing hormone, testosterone, corticosterone, thyroid-stimulating hormone and glucose, and pineal melatonin content, in rats. Esquifino AI Endocrine 2008, 33:118-125.
6. Chakravarthy M.V., Pan Z., Zhu Y., Tordjman K., Schneider J.G., Coleman T., Turk J., Semenkovich C.F. New hepatic fat activates PPARalpha to maintain glucose, lipid, and cholesterol homeostasis. Cell Metab. 2005, 1:309-322.
7. Chao F., Gong W., Zheng Y., Li Y., Huang G., Gao M., Li J., Kuruba R., Gao X., Li S., He F. Upregulation of scavenger receptor class B type I expression by activation of FXR in hepatocyte. Atherosclerosis 2010, 213:443-448.
8. Cheng X., Ding J., Zheng F., Zhou X., Xiong C. Two mutations in LDLR gene were found in two Chinese families with familial hypercholesterolemia. Mol. Biol. Rep. 2009, 36:2053-2057.
9. Dong H., Lu F.E., Zhao L. Chinese herbal medicine in the treatment of nonalcoholic fatty liver disease. Chin. J. Integr. Med. 2012, 18:152-160.
10. Dorn C., Riener M.O., Kirovski G., Saugspier M., Steib K., Weiss T.S., Gäbele E., Kristiansen G., Hartmann A., Hellerbrand C. Expression of fatty acid synthase in nonalcoholic fatty liver disease. Int. J. Clin. Exp. Pathol. 2010, 3:505-514.
11. Farrell G.C., Chitturi S., Lau G.K., Sollano J.D. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J. Gastroenterol. Hepatol. 2007, 22:775-777.
12. Gaemers I.C., Groen A.K. New insights in the pathogenesis of non-alcoholic fatty liver disease. Curr. Opin. Lipidol. 2006, 17:268-273.
13. Gómez-Zorita S., Fernández-Quintela A., Macarulla M.T., Aguirre L., Hijona E., Bujanda L., Milagro F., Martínez J.A., Portillo M.P. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br. J. Nutr. 2012, 107:202-210.
14. Hajiaghamohammadi A.A., Ziaee A., Samimi R. The efficacy of licorice root extract in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial. Phytother. Res. 2012, 10.1002/ptr.3728.
15. Issandou M. Pharmacological regulation of low density lipoprotein receptor expression: current status and future developments. Pharmacol. Ther. 2006, 111:424-433.
16. Jiang Q., Li Y., Pan J., Ma J., Xu B., Yang H., Zhang J., He M. TNF-alpha gene expression of NAFLD rat intervened by the extracts of Rizoma Polygoni Cuspidati. Zhong Yao Cai. 2005, 28:917-920.
17. Jourdan T., Djaouti L., Demizieux L., Gresti J., Vergès B., Degrace P. CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010, 59:926-934.
18. Karlsson J., Emgard M., Brundin P., Burkitt M.J. Trans-resveratrol protects embryonic mesencephalic cells from tert-butyl hydroperoxide: electron paramagnetic resonance spin trapping evidence for a radical scavenging mechanism. J. Neurochem. 2000, 75:141-150.
19. Kohjima M., Enjoji M., Higuchi N., Kato M., Kotoh K., Yoshimoto T., Fujino T., Yada M., Yada R., Harada N., Takayanagi R., Nakamuta M. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int. J. Mol. Med. 2007, 20:351-358.
20. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
21. Lee M.S., Kim D., Jo K., Hwang J.K. Nordihydroguaiaretic acid protects against high-fat diet-induced fatty liver by activating AMP-activated protein kinase in obese mice. Biochem. Biophys. Res. Commun. 2010, 401:92-97.
22. Leng L., Jiang Z.Q., Ji G.Y. Effects of soybean isoflavone on liver lipid metabolism in nonalcoholic fatty liver rats. Zhonghua Yu Fang Yi Xue Za Zhi. 2011, 45:335-339.
23. Lopez D., Abisambra, Socarrás J.F., Bedi M., Ness G.C. Activation of the hepatic LDL receptor promoter by thyroid hormone. Biochim. Biophys. Acta 2007, 1771:1216-1225.
24. Maher M.A., Banz W.J., Truett G.E., Zemel M.B. Dietary fat and sex modify heterozygote effects of the rat fatty (fa) allele. J. Nutr. 1996, 126:2487-2493.
25. Morgan K., Uyuni A., Nandgiri G., Mao L., Castaneda L., Kathirvel E., French S.W., Morgan T.R. Altered expression of transcription factors and genes regulating lipogenesis in liver and adipose tissue of mice with high fat diet-induced obesity and nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 2008, 20:843-854.
26. Musso G., Gambino R., Cassader M. Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog. Lipid Res. 2009, 48:1-26.
27. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 2003, 37:1202-1219.
28. Redonnet A., Groubet R., Noël-Suberville C., Bonilla S., Martinez A., Higueret P. Exposure to an obesity-inducing diet early affects the pattern of expression of peroxisome proliferator, retinoic acid, and triiodothyronine nuclear receptors in the rat. Metabolism 2001, 50:1161-1167.
29. Shang J., Chen L.L., Xiao F.X., Sun H., Ding H.C., Xiao H. Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacol. Sin. 2008, 29:698-706.
30. Sahebkar A. Citrus auraptene: a potential multifunctional therapeutic agent for nonalcoholic fatty liver disease. Ann. Hepatol. 2011, 10:575-577.
31. Shin D.J., Osborne T.F. Thyroid hormone regulation and cholesterol metabolism are connected through sterol regulatory element-binding protein-2 (SREBP-2). J. Biol. Chem. 2003, 278:34114-34118.
32. Spady D.K. Hepatic clearance of plasma low density lipoproteins. Semin. Liver Dis. 1992, 12:373-385.
33. Suriyavathana Vedanarayanan M., Krishnan N. Ayurvedic formulation of Liv-Pro-08 reduces nonalcoholic fatty liver disease in rats fed with high-fat diet. J. Acupunct. Meridian. Stud. 2011, 4:236-241.
34. Varban M.L., Rinninger F., Wang N., Fairchild-Huntress V., Dunmore J.H., Fang Q., Gosselin M.L., Dixon K.L., Deeds J.D., Acton S.L., Tall A.R., Huszar D. Targeted mutation reveals a central role for SRBI in hepatic selective uptake of high density lipoprotein cholesterol. Proc. Natl. Acad. Sci. USA 1998, 95:4619-4624.
35. Varret M., Abifadel M., Rabès J.P., Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin. Genet. 2008, 73:1-13.
36. Vijayakumar M.V., Pandey V., Mishra G.C., Bhat M.K. Hypolipidemic effect of fenugreek seeds is mediated through inhibition of fat accumulation and upregulation of LDL receptor. Obesity (Silver Spring). 2010, 18:667-674.
37. Wang L., Meng X., Zhang F. Raspberry ketone protects rats fed high-fat diets against nonalcoholic steatohepatitis. J. Med. Food 2012, 15:495-503.
38. Wilson T., Knight T.J., Beitz D.C., Lewis D.S., Engen R.L. Resveratrol promotes atherosclerosis in hypercholesterolemic rabbits. Life Sci. 1996, 59:15-21.
39. Yashiro T., Nanmoku M., Shimizu M., Inoue J., Sato R. Resveratrol increases the expression and activity of the low density lipoprotein receptor in hepatocytes by the proteolytic activation of the sterol regulatory element-binding proteins. Atherosclerosis 2012, 220:369-374.
40. Zern T.L., West K.L., Femandez M.L. Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. J. Nutr. 2003, 133:2268-2272.